Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 19/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 14/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 8/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3704286 | 1.00 | ADRB3 (0.60) | ADRB3ADRB1ALOX15ADRB2 | |
| SCHEMBL3704289 | 0.89 | ADRB3 (0.58) | ADRB3ADRB1ALOX15ADRB2 | |
| SCHEMBL8477156 | 0.87 | ADRB3 (0.65) | ADRB3ADRB1ALOX15ADRB2 | |
| SCHEMBL6925853 | 0.87 | ADRB3 (0.65) | ADRB3ADRB1ALOX15ADRB2 | |
| SCHEMBL667781 | 0.87 | ADRB3 (0.62) | ADRB3ADRB1ALOX15ADRB2 | |
| SCHEMBL8477150 | 0.87 | ADRB3 (0.65) | ADRB3ADRB1ALOX15ADRB2 | |
| SCHEMBL6925856 | 0.87 | ADRB3 (0.65) | ADRB3ADRB1ALOX15ADRB2 | |
| SCHEMBL6925849 | 0.87 | ADRB3 (0.65) | ADRB3ADRB1ALOX15ADRB2 | |
| SCHEMBL667783 | 0.87 | ADRB3 (0.62) | ADRB3ADRB1ALOX15ADRB2 | |
| SCHEMBL8129752 | 0.87 | ADRB3 (0.65) | ADRB3ADRB1ALOX15ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | METABASIS THERAPEUTICS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20190083515-A1 | THYROMIMETICS FOR THE TREATMENT OF FATTY LIVER DISEASES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-03-21 | — | — | US | disclosed |
| US-10130643-B2 | Thyromimetics for the treatment of fatty liver diseases | METABASIS THERAPEUTICS, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| WO-2017184811-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | METABASIS THERAPEUTICS, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| US-20170112864-A1 | Thyromimetics for the Treatment of Fatty Liver Diseases | METABASIS THERAPEUTICS, INC. (US) | 2017-04-27 | — | — | US | disclosed |
| EP-1689383-B1 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS INC (US) | 2012-10-31 | — | — | EP | disclosed |
| WO-2010093601-A1 | NOVEL SULFONIC ACID-CONTAINING THYROMIMETICS, AND METHODS FOR THEIR USE | METABASIS THERAPEUTICS, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| US-7514419-B2 | Phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1898926-A2 | THYROMIMETICS FOR THE TREATMENT OF FATTY LIVER DISEASES | Metabasis Therapeutics, Inc. (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1891080-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | Metabasis Therapeutics, Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1890768-A2 | NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS | Metabasis Therapeutics, Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006128058-A2 | THYROMIMETICS FOR THE TREATMENT OF FATTY LIVER DISEASES | METABASIS THERAPEUTICS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006128056-A2 | NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006128055-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060046980-A1 | Novel phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112864-A1 | Thyromimetics for the Treatment of Fatty Liver Diseases | TSHR, THRA, FABP1 | ADRB3 148/4885ADRB1 261/4885ALOX15 314/4885 |
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | TSHR, THRA, FABP1 | ADRB3 148/4885ADRB1 261/4885ALOX15 314/4885 |
| US-20190083515-A1 | THYROMIMETICS FOR THE TREATMENT OF FATTY LIVER DISEASES | TSHR, THRA, FABP1 | ADRB3 139/4885ADRB1 251/4885ALOX15 314/4885 |
| US-20060046980-A1 | Novel phosphorus-containing thyromimetics | PYGL, THRA, THOP1 | ADRB3 1247/4885ADRB1 2591/4885ALOX15 1968/4885 |
| US-10130643-B2 | Thyromimetics for the treatment of fatty liver diseases | TSHR, THRA, FABP1 | ADRB3 148/4885ADRB1 261/4885ALOX15 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.